close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

SAB Biotherapeutics, Inc. - Warrant (NQ:SABSW)

0.0297 +0.0004 (+1.37%)
Streaming Delayed Price Updated: 3:50 PM EST, Nov 21, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about SAB Biotherapeutics, Inc. - Warrant

< Previous 1 2 3 Next >
News headline image
SAB Biotherapeutics Successfully Concludes IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes
Study shows SAB’s fully-human polyclonal therapeutic that has potential to delay the onset or progression of type 1 diabetes is well tolerated; next step is investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics’ CMO Alexandra Kropotova to Deliver Presentation on Next Generation Biologics in Immunology at Biotech Showcase
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Novel DiversitAb™ Platform Proven to Develop Anti-idiotype Antibodies to Help Treat Autoimmune Diseases
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics CMO Selected to Present at the January 2023 Biotech Showcase in San Francisco
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces $7.9 Million Private Placement of Common Stock
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Initiates IND-Enabling GLP Toxicology Study for SAB-142, Novel Immunotherapeutic for Type 1 Diabetes
Study of SAB’s fully-human polyclonal therapeutic to delay onset or progression of type 1 diabetes is the last step before investigational new drug (IND) filing 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Provides Company Update for Q3 2022 Financial Results
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Presents ‘Novel Biologic Therapeutics for Infectious Diseases’ at U.S. Pharma Partnering Summit 2022
Eddie Sullivan, Co-Founder, President and CEO, to present as SAB Biotherapeutics continues to execute on its partnering focused business strategy 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Presents Overview of DiversitAb™ Platform and Data Showing Benefits of Fully-Human Polyclonal Antibodies Derived from Cows vs. Human-Derived Plasma, at 2022 Plasma Product Biotechnology Conference
SAB highlights data on SAB-176 for seasonal and pandemic influenza and SAB-185 for COVID-19, showing broad efficacy against highly mutating viruses associated with respiratory disease 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Announces Exclusive Manufacturing Partnership with Emergent BioSolutions
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
SAB Biotherapeutics Unveils New Data at ISIRV OPTIONS XI Conference Validating SAB-176 Proof of Concept in Reducing Viral Load and Improving Symptoms of Influenza and Showing SAB-185 Effective Against Multiple COVID-19 Variants Including Omicron
SAB’s fully-human polyclonal antibody platform maintains its efficacy against multiple variants of several highly mutating viruses 
From SAB Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today